Recombinant Human CLDN18.1 (N-8His)

Recombinant Human CLDN18.1 (N-8His)

Size1:10μg price1:$245
Size2:50μg price2:$620
Size3:500μg price3:$3100
SKU: PEH2036 Category: Target Proteins Tags: ,

Datasheet

Name

Recombinant Human CLDN18.1 (N-8His)

Purity

Greater than 95% as determined by reducing SDS-PAGE

Endotoxin level

<1 EU/µg as determined by LAL test.

Construction

Recombinant Human CLDN18.1 is produced by our E.coli expression system and the target gene encoding Asp28-Leu76 is expressed with a 8His tag at the N-terminus.

Accession #

P56856

Host

E.coli

Species

Human

Predicted Molecular Mass

19.8 KDa

Buffer

Supplied as a 0.2 μm filtered solution of 20mM Tris-HCl, 8% Sucrose, 2% Glycine, 20% Glycerol, 5mM DTT, 0.05% Tween 80, pH 8.0.

Form

Liquid

Shipping

The product is shipped on dry ice/polar packs.Upon receipt, store it immediately at the temperature listed below.

Stability&Storage

Store at ≤-70°C, stable for 6 months after receipt.Store at ≤-70°C, stable for 3 months under sterile conditions after opening. Please minimize freeze-thaw cycles.

 

 

 

Alternative Names

Claudin-18; CLDN18

 

Background

Claudin-18(CLDN18) is a protein that in humans is encoded by the CLDN18 gene. It belongs to the group of claudins. CLDN18 belongs to the large claudin family of proteins, which form tight junction strands in epithelial cells. CLDN18 plays a major role in tight junction-specific obliteration of the intercellular space, through calcium-independent cell-adhesion activity. CLDN18 has two isoform A1 and isoform A2. IMAB362 (Claudiximab) is a monoclonal antibody against isoform 2 of Claudin-18. It is under investigation for the treatment of gastrointestinal adenocarcinomas and pancreatic tumors. IMAB362 was developed by Ganymed Pharmaceuticals AG.

 

Note

For Research Use Only , Not for Diagnostic Use.